Trial · NCT07881055
Cryptococcosis Associated With Bruton Tyrosine Kinase Inhibitors
NCT07881055, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cryptococcosis Associated With Bruton Tyrosine Kinase Inhibitors. Trials, record NCT07881055. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881055
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cryptococcosis Associated With Bruton Tyrosine Kinase Inhibitors
- NCT number
- NCT07881055
- Status
- Not yet recruiting
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Cryptococcosis
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical manifestations description of cryptococcosis | 1 day | Number of clinical manifestations and description of cryptococcosis at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors. |
| Primary | Infection sites of cryptococcosis | 1 day | Type of infection sites in cryptococcosis patients at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors. |
| Primary | Microbiological and mycological data description of cryptococcosis | 1 day | Microbiological and mycological data in cryptococcosis patients at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors. |
| Primary | Biological parameters of cryptococcosis | 1 day | Biological parameters of cryptococcosis at the time of diagnosis in patients with hematologic malignancies treated with BTK inhibitors. |
| Secondary | Patients' baseline characteristics | 12 months | Description of the patients' baseline characteristics, including : * demographic characteristics, * comorbidities, * type of hematologic malignancy, * history and lines of prior treatment, particularly immunosuppressive therapies; |
| Secondary | Time between cryptococcosis relative to the initiation of BTK inhibitor | 12 months | Time to onset of cryptococcosis relative to the initiation of BTK inhibitor (BTKi) treatment by collecting patient's medical history |
| Secondary | Clinical cryptococcosis | 12 months | Symptoms and collection of the cryptococcosis by collecting patient's medical history |
| Secondary | Therapeutic management | 12 months | Therapeutic management of the cryptococcosis by collecting patient's undergone treatments |
| Secondary | Mortality | 12 months | All-cause mortality by collecting patient's life status |
| Secondary | Treatment outcome | 12 months | Outcome of BTKi treatment, including discontinuation, continuation, or resumption of treatment following the cryptococcosis episode. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881055
GET https://conductscience.org/api/trials/v1/NCT07881055/registered